1- Faculty of Technical Engineering, Golestan University, Gorgan, Iran
2- Department of Computer Engineering, Faculty of Technical Engineering, Golestan University, Gorgan, Iran ,mehdi.yaghoubi@gmail.com
2- Department of Computer Engineering, Faculty of Technical Engineering, Golestan University, Gorgan, Iran ,
Abstract: (422 Views)
Background: Identifying drug-target interactions (DTIs) is a central focus in pharmaceutical research, as accurately recognizing these interactions can play a crucial role in developing modern and targeted therapies. In recent years, numerous deep learning-based models have been introduced to predict these interactions. However, several challenges remain. Existing methods often fail to incorporate the three-dimensional structures of drugs and proteins alongside their SMILES and FASTA sequences, resulting in lower prediction accuracy. Furthermore, many approaches utilize only partial sequence data, thereby overlooking critical information. This lack of spatial and comprehensive sequence awareness ultimately limits the accurate modeling of molecular interactions and binding mechanisms.
Methods: In this study, we introduced TGATS2S-v1 and TGATS2S-v2, two novel deep learning frameworks designed to address the critical challenge of Drug-Target Interaction (DTI) prediction by integrating 3D structural information of both drugs and target proteins alongside their canonical sequence representations (SMILES and FASTA). The proposed methods leveraged three-dimensional structural information to enhance DTI prediction and were tested on the Davis dataset.
Results: The results of the proposed methods were thoroughly analyzed. By integrating 3D structural data, the predictive power of the models improved significantly. Evaluations showed that these models consistently outperformed advanced baseline models, delivering higher accuracy and robustness in all cases. The proposed model achieves state-of-the-art performance, improving PR-AUC by over 20%.
Conclusion: These findings indicate that incorporating 3D structural information plays a pivotal role in overcoming the limitations of previous models and paves the way for the discovery of more effective drugs and therapeutic advancements.
Methods: In this study, we introduced TGATS2S-v1 and TGATS2S-v2, two novel deep learning frameworks designed to address the critical challenge of Drug-Target Interaction (DTI) prediction by integrating 3D structural information of both drugs and target proteins alongside their canonical sequence representations (SMILES and FASTA). The proposed methods leveraged three-dimensional structural information to enhance DTI prediction and were tested on the Davis dataset.
Results: The results of the proposed methods were thoroughly analyzed. By integrating 3D structural data, the predictive power of the models improved significantly. Evaluations showed that these models consistently outperformed advanced baseline models, delivering higher accuracy and robustness in all cases. The proposed model achieves state-of-the-art performance, improving PR-AUC by over 20%.
Conclusion: These findings indicate that incorporating 3D structural information plays a pivotal role in overcoming the limitations of previous models and paves the way for the discovery of more effective drugs and therapeutic advancements.
Keywords: Drug-Target Interaction (Drug Delivery Systems), 3D structure, Graph Attention Network, Convolutional Neural Networks, Attention Mechanism
Type of Article: Original article |
Subject:
Bio-statistics
Received: 2025/02/19 | Accepted: 2025/03/25
Received: 2025/02/19 | Accepted: 2025/03/25
References
1. Zeng X, Zhu S, Lu W, Liu Z, Huang J, Zhou Y, et al. Target identification among known drugs by deep learning from heterogeneous networks. Chem Sci. 2020;11(7):1775-97. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Zeng X, Zhu S, Liu X, Zhou Y, Nussinov R, Cheng F. deepDR: a network-based deep learning approach to in silico drug repositioning. Bioinformatics. 2019;35(24):5191-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-14. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Zeng X, Wang F, Luo Y, Kang S-G, Tang J, Lightstone FC, et al. Deep generative molecular design reshapes drug discovery. Cell Rep Med.
2022;3(12):100794. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Ye Q, Hsieh C-Y, Yang Z, Kang Y, Chen J, Cao D, et al. A unified drug-target interaction prediction framework based on knowledge graph and recommendation system. Nat Commun. 2021;12(1):6775. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Bagherian M, Sabeti E, Wang K, Sartor MA, Nikolovska-Coleska Z, Najarian K. Machine learning approaches and databases for prediction of drug-target interaction: a survey paper. Brief Bioinform. 2021;22(1):247-69. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Lecun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-44. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Otter DW, Medina JR, Kalita JK. A Survey of the Usages of Deep Learning for Natural Language Processing. IEEE Trans Neural Netw Learn Syst.
2021;32(2):604-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Arulkumaran k, Deisenroth MP, Brundage M, Bharath AA. Deep Reinforcement Learning: A Brief Survey. IEEE Signal Process Mag. 2017;34(6):26- 38. [View at Publisher] [DOI] [Google Scholar]
11. Ciresan D, Meier U, Masci J, Schmidhuber J. Multi-column deep neural network for traffic sign classification. Neural Netw. 2012:32:333-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Krizhevsky A, Sutskever I, Hinton GE. ImageNet classification with deep convolutional neural networks. Commun ACM. 2017;60(6):84-90. [View at Publisher] [DOI] [Google Scholar]
13. Huang K, Xiao C, Glass LM, SunJ. MolTrans: Molecular Interaction Transformer for drug-target interaction prediction. Bioinformatics. 2021;37(6):830-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Lee I, Keum J, Nam H. DeepConv-DTI: Prediction of drug-target interactions via deep learning with convolution on protein sequences. PLoS Comput Biol. 2019;15(6):e1007129. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Tsubaki M, Tomii K, Sese J. Compound-protein interaction prediction with end-to-end learning of neural networks for graphs and sequences. Bioinformatics. 2019;35(2);309-18. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Öztürk H, Özgür A, Ozkirimli E. DeepDTA: deep drug-target binding affinity prediction. Bioinformatics. 2018;34(17):i821-i9. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Wen M, Zhang Z, Niu S, Sha H, Yang R, Yun Y, et al. Deep-Learning-Based Drug-Target Interaction Prediction. J Proteome Res. 2017;16(4):1401-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol.
2011;29(11);1046-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Cox DR. The Regression Analysis of Binary Sequences. J R Stat Soc Series B Stat Methodol. 1958;20(2):215-32. [View at Publisher] [DOI] [Google Scholar]
20. Su Y, Guo J, Ling H, Chen S, Wang S, Xu L, et al. Isolation of a novel peroxisomal catalase gene from sugarcane, which is responsive to biotic and abiotic stresses. PLoS One. 2014;9(1):e84426. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
